Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START fingolimod first-dose cardiac conduction study
2012-000653-32Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Incidence of bradycardia and bradyarrhythmic ECG events during the 6-hour monitoring period after first fingolimod dose. Started Apr 2012; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-000653-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000653-32.